Danny Tal, director of import administration at Israel's Ministry of Economy and Industry, said in a letter addressed to Michael Mancini, chief commercial counselor for the Embassy of Canada in Israel, that he has found a connection between these imports and damaging effects on Israel’s domestic cannabis industry.
"I wish to inform you that after I found that special circumstances exist, I have decided to initiate an Anti-Dumping investigation concerning the importation of medical cannabis from Canada," Tal said. "Our findings, regarding whether there is dumping, consequent injury and the duty required, will be determined on the basis of best information available."
The period of investigation for anti-dumping activities will be between Jan. 1, 2023 and Dec. 31, 2023, and for damages to local business between Jan. 1, 2021 to Dec. 31, 2023.
The following companies have a 30-day deadline to submit "information, evidence and their arguments” in addition to answering a questionnaire:
Cannabis In Israel
One of the first countries to recognize the benefits of medical cannabis in the 1990s, Israel is set to see exponential growth in the burgeoning market as a new set of reforms set to be implemented over the coming months.
Related News
Benzinga Cannabis Conferences are coming to Los Angeles. Join the Benzinga Cannabis Market Spotlight: California, and unlock the future of cannabis at the premier networking event in Culver City on Feb. 22.
Connect with top industry leaders, gain insider insights into the investment landscape and shape the evolving markets in California and beyond. Don't miss this chance to be at the forefront of the cannabis industry's growth and innovation! Join now.
Photo: Courtesy of Taylor Brandon on Unsplash
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
